Health & bio
Nuvation Bio Files IBTROZI sNDA for ROS1-Positive NSCLC
Nuvation Bio submitted a supplemental NDA on 5/6 for IBTROZI (taletrectinib) in advanced ROS1-positive NSCLC. Target action date: January 4, 2027.
Primary sources · 1
Nuvation Bio submitted a supplemental NDA on 5/6 for IBTROZI (taletrectinib) in advanced ROS1-positive NSCLC. Target action date: January 4, 2027.
7 must-reads · 17 fields · tracked storylines delivered to your inbox daily. Pick only the fields you want; unsubscribe anytime.